As central banks in major economies hold interest rates steady amid geopolitical uncertainties, the Asian markets are navigating a complex landscape of currency fluctuations and evolving policy expectations. In this environment, identifying stocks that may be priced below their estimated value requires careful consideration of factors such as earnings resilience and sector-specific growth potential.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) |
HK$456.80 |
HK$892.96 |
48.8% |
|
SHIFT (TSE:3697) |
¥649.40 |
¥1274.37 |
49% |
|
Shanghai Putailai New Energy Technology GroupLtd (SHSE:603659) |
CN¥36.27 |
CN¥71.18 |
49% |
|
Premium Group (TSE:7199) |
¥1864.00 |
¥3665.16 |
49.1% |
|
KINX (KOSDAQ:A093320) |
₩106700.00 |
₩212459.46 |
49.8% |
|
JAC Recruitment (TSE:2124) |
¥851.00 |
¥1688.22 |
49.6% |
|
Inner Mongolia Xingye Silver & Tin Mining (SZSE:000426) |
CN¥42.38 |
CN¥84.50 |
49.8% |
|
HD-Hyundai Marine Engine (KOSE:A071970) |
₩107100.00 |
₩208484.21 |
48.6% |
|
Elan (TSE:6099) |
¥760.00 |
¥1478.86 |
48.6% |
|
ALT (KOSDAQ:A459550) |
₩2900.00 |
₩5744.65 |
49.5% |
Let’s uncover some gems from our specialized screener.
Overview: Shanghai MicroPort MedBot (Group) Co., Ltd. operates in the medical technology sector, focusing on the development and commercialization of surgical robots, with a market cap of approximately HK$32.65 billion.
Operations: The company generates revenue primarily from the sale of medical devices, amounting to CN¥551.07 million.
Estimated Discount To Fair Value: 16.1%
Shanghai MicroPort MedBot (Group) is trading at HK$31.66, below its estimated future cash flow value of HK$37.74, suggesting it may be undervalued based on cash flows. The company’s revenue is forecast to grow significantly at 30.4% per year, outpacing the Hong Kong market’s growth rate of 8.5%. Recent financials show a reduction in net loss from CNY 642.41 million to CNY 249.66 million in 2025, alongside robust global expansion and adoption of its Toumai Laparoscopic Surgical Robot system.
Overview: Singapore Technologies Engineering Ltd is a global technology, defence, and engineering company with a market cap of SGD33.68 billion.
Operations: The company’s revenue is derived from three main segments: Commercial Aerospace at SGD5.04 billion, Urban Solutions & Satcom at SGD2.08 billion, and Defence & Public Security at SGD5.39 billion.